--Chardan Capital Adjusts SAB Biotherapeutics' Price Target to $7 from $10, Keeps Buy Rating
MT Newswires · 05/13 11:07
SAB Biotherapeutics GAAP EPS of $0.02
SAB Biotherapeutics press release (NASDAQ:SABS): Q1 GAAP EPS of $0.02. Cash and cash equivalents were $22.4 million as of March 31, 2022, compared to $33.2 million on December 31, 2021.
Seekingalpha · 05/12 21:11
BRIEF-SAB Biotherapeutics Reports Q1 EPS Of $0.02 · 05/12 20:23
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later this year Sufficient cash anticipated...
GlobeNewswire · 05/12 20:15
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May 23-26, 2022. As part of the conference, the company’s manag...
GlobeNewswire · 05/12 13:42
Shareholders in SAB Biotherapeutics (NASDAQ:SABS) are in the red if they invested a year ago
As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...
Simply Wall St. · 05/05 12:34
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 139% to $5.40 after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
Benzinga · 04/05 16:12
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibo...
GlobeNewswire · 04/05 10:00
BBIG, NAOV and ISPO among pre market losers
SELLAS Life Sciences SLS -39% plunged 24% on $25M stock offering. ARCA biopharma ABIO -22% fails to meet key goal in mid-stage trial for COVID-19 therapy. Redwire RDW -18% on Q4 results. Blend Labs BLND -18% on
Seekingalpha · 04/01 12:41
--Chardan Adjusts SAB Biotherapeutics Price Target to $10 From $17, Maintains Buy Rating
MT Newswires · 04/01 10:30
VTNR, MF and SABS among mid-day movers
Gainers: Longeveron (LGVN) +62%. Clovis Oncology (CLVS) +61%. Icosavax (ICVX) +26%. Integrated Media Technology (IMTE) +28%. SAB Biotherapeutics (SABS) +21%. Local Bounti (LOCL) +21%. CPS Technologies (CPSH) +18%. Vector Group
Seekingalpha · 03/31 16:49
SAB Biotherapeutics GAAP EPS of -$0.63
SAB Biotherapeutics press release (SABS): FY GAAP EPS of -$0.63.  Cash and cash equivalents were $33.2M as of December 31, 2021, as compared to $12.6M as of December 31, 2020.
Seekingalpha · 03/29 20:57
Mid-Afternoon Market Update: Dow Gains 2%; SAB Biotherapeutics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 2% on Wednesday.
Benzinga · 03/02 19:47
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.
Benzinga · 03/02 17:41
Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels
U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday.
Benzinga · 03/02 17:10
Mid-Morning Market Update: U.S. Stocks Mixed; Dollar Tree Reports Mixed Q4 Results
U.S. stocks opened mixed this morning, with the Dow Jones adding more than 200 points on Wednesday.
Benzinga · 03/02 15:30
BRIEF-SAB Biotherapeutics Announces Publication Of Nonclinical Data Demonstrating SAB-185 Has High Potency For Effectively Neutralizing Circulating And Emerging Sars-Cov-2 Variants · 03/02 14:22
NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185
Benzinga · 03/02 14:13
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 03/02 12:50
BRIEF-Sab Biotherapeutics Reports NIH Is Discontinuing Phase 3 Activ-2 Trial Assessing Sab-185 · 03/02 12:31
Webull provides a variety of real-time SABS stock news. You can receive the latest news about SAB BIOTHERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About SABS
SAb Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.